Emerging Markets to Drive Biotech in 2011
January 03 2011 - 10:25AM
Marketwired
Biotech companies have not been impervious to the economic
downturn, but they have endured better than most. This is due in
part to the fact that demand for pharmaceuticals remains fairly
constant even during recession. As 2011 kicks off there is plenty
of optimism regarding the Biotech Industry as firmer pricing and
new products have improved sales and earnings trends. Moreover --
similar to last year -- Merger & Acquisition activity is likely
to play a large part throughout the sector. The Bedford Report
examines the outlook for companies in the Biotechnology Industry
and provides research reports on Sunesis Pharmaceuticals, Inc.
(NASDAQ: SNSS) and AEterna Zentaris, Inc. (NASDAQ: AEZS). Access to
the full company reports can be found at:
www.bedfordreport.com/2011-01-SNSS
www.bedfordreport.com/2011-01-AEZS
The healthcare industry research firm IMS Health projects an
increase in worldwide growth in 2011. The firm forecasts 5% to 7%
versus a pace of 4% to 5% in 2010. The firm has a meager growth
outlook until at least 2015.
Much of the growth is expected to come from emerging markets
such as China, Brazil, India and South Korea. These countries are
benefiting from increased government spending on health care and
more extensive private health coverage for workers. IMS predicts
sales growth of 15% in these markets.
The Bedford Report releases regular market updates on the
Biotechnology Industry so investors can stay ahead of the crowd and
make the best investment decisions to maximize their returns. Take
a few minutes to register with us free at www.bedfordreport.com and
get exclusive access to our numerous analyst reports and industry
newsletters.
In recent Biotech news, the Obama administration pressed
congress to revamp a research and development tax credit by
increasing it by about 20 percent and make it permanent. The
Pharmaceutical Research and Manufacturers of America, PhRMA, as
well as the Advanced Medical Technology Association expressed
support for the tax credit.
The Bedford Report provides Analyst Research focused on equities
that offer growth opportunities, value, and strong potential
return. We strive to provide the most up-to-date market activities.
We constantly create research reports and newsletters for our
members. The Bedford Report has not been compensated by any of the
above-mentioned companies. We act as an independent research portal
and are aware that all investment entails inherent risks. Please
view the full disclaimer at:
http://www.bedfordreport.com/disclaimer.php.
Add to Digg Bookmark with del.icio.us Add to Newsvine
Contact: The Bedford Report Email Contact
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Jul 2024 to Aug 2024
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Aug 2023 to Aug 2024
Real-Time news about Sunesis Pharmaceuticals Inc (NASDAQ): 0 recent articles
More The Bedford Report News Articles